[Hope for gene therapy. Is this the future of tumor treatment?].

Publication type:
Journal article
Metadata:
Abstract
Conventional antineoplastic chemotherapy is limited by the low binding specificity of cytostatic agents and the ubiquity of critical target molecules in both neoplastic and normal cells. Recent advances in molecular biology have led to the identification of ever more genetic alterations specific to tumor cells that may serve as targets for gene therapy. Since appropriately designed nucleic acids hybridize to their "target nucleic acid" with extremely high binding specificity, and can be prepared with relative ease, gene therapy is theoretically superior to conventional chemotherapy. However, the low efficacy of currently available gene transfer technologies, the redundancy of genetic control mechanisms, and, for example under antitumor treatment, the multitude of genetic alterations accumulating during tumor progression represent significant problems. With the exception of monogenic disease, therefore, most clinical studies have so far demonstrated the feasibility of gene therapy, rather than its therapeutic efficacy. Ethical considerations rule out germline therapy. In comparison with conventional treatment, the assessment of the risks of this form of therapy should include a consideration of irreversible and reversible damage.
Addresses
  • Medizinische Klinik IV, Universitätsklinikum, RWTH Aachen.
Autoren
eISSN
1613-3560
Externe Identifier
  • PubMed Identifier: 11468994
Open access
false
ISSN
1438-3276
Ausgabe der Veröffentlichung
25
Zeitschrift
MMW Fortschritte der Medizin
Schlüsselwörter
  • Animals
  • Humans
  • Neoplasms
  • Chromosome Aberrations
  • Risk Factors
  • Feasibility Studies
  • Gene Transfer Techniques
  • Forecasting
  • Genetic Therapy
Sprache
ger
Medium
Print
Paginierung
33 - 36
Datum der Veröffentlichung
2001
Status
Published
Datum der Datenerfassung
2001
Titel
[Hope for gene therapy. Is this the future of tumor treatment?].
Sub types
  • Journal Article
  • English Abstract
Ausgabe der Zeitschrift
143

Data source: Europe PubMed Central

Other metadata sources:
Abstract
Conventional antineoplastic chemotherapy is limited by the low binding specificity of cytostatic agents and the ubiquity of critical target molecules in both neoplastic and normal cells. Recent advances in molecular biology have led to the identification of ever more genetic alterations specific to tumor cells that may serve as targets for gene therapy. Since appropriately designed nucleic acids hybridize to their "target nucleic acid" with extremely high binding specificity, and can be prepared with relative ease, gene therapy is theoretically superior to conventional chemotherapy. However, the low efficacy of currently available gene transfer technologies, the redundancy of genetic control mechanisms, and, for example under antitumor treatment, the multitude of genetic alterations accumulating during tumor progression represent significant problems. With the exception of monogenic disease, therefore, most clinical studies have so far demonstrated the feasibility of gene therapy, rather than its therapeutic efficacy. Ethical considerations rule out germline therapy. In comparison with conventional treatment, the assessment of the risks of this form of therapy should include a consideration of irreversible and reversible damage.
Autoren
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/11468994
ISSN
1438-3276
Ausgabe der Veröffentlichung
25
Zeitschrift
MMW Fortschr Med
Schlüsselwörter
  • Animals
  • Chromosome Aberrations
  • Feasibility Studies
  • Forecasting
  • Gene Transfer Techniques
  • Genetic Therapy
  • Humans
  • Neoplasms
  • Risk Factors
Sprache
ger
Country
Germany
Paginierung
33 - 36
Datum der Veröffentlichung
2001
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2001
Titel
[Hope for gene therapy. Is this the future of tumor treatment?].
Sub types
  • English Abstract
  • Journal Article
Ausgabe der Zeitschrift
143

Data source: PubMed

Beziehungen:
Property of

Tools